Your browser doesn't support javascript.
loading
Engineering Chimeric Antigen Receptors.
Kulemzin, S V; Kuznetsova, V V; Mamonkin, M; Taranin, A V; Gorchakov, A A.
Afiliação
  • Kulemzin SV; Institute of Molecular and Cellular Biology, SB RAS, Lavrentiev Ave. 8/2, Novosibirsk, 630090, Russia.
  • Kuznetsova VV; Institute of Molecular and Cellular Biology, SB RAS, Lavrentiev Ave. 8/2, Novosibirsk, 630090, Russia.
  • Mamonkin M; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX, USA.
  • Taranin AV; Institute of Molecular and Cellular Biology, SB RAS, Lavrentiev Ave. 8/2, Novosibirsk, 630090, Russia.
  • Gorchakov AA; Novosibirsk State University, Pirogova str. 2, Novosibirsk, 630090, Russia.
Acta Naturae ; 9(1): 6-14, 2017.
Article em En | MEDLINE | ID: mdl-28461969
ABSTRACT
Chimeric antigen receptors (CARs) are recombinant protein molecules that redirect cytotoxic lymphocytes toward malignant and other target cells. The high feasibility of manufacturing CAR-modified lymphocytes for the therapy of cancer has spurred the development and optimization of new CAR T cells directed against a broad range of target antigens. In this review, we describe the main structural and functional elements constituting a CAR, discuss the roles of these elements in modulating the anti-tumor activity of CAR T cells, and highlight alternative approaches to CAR engineering.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Acta Naturae Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Acta Naturae Ano de publicação: 2017 Tipo de documento: Article